Psychiatry Collaboration and Licensing Deals 2019-2026

Key Benefits

✔ Benchmark against 612 psychiatry partnering deals – Access a substantial body of real-world collaboration and licensing activity to identify relevant precedents and comparable transactions.

✔ Benchmark psychiatry deal financials – Analyze disclosed headline values, upfront payments, milestones and royalty rates and investigate the individual transactions behind the benchmarks.

✔ Identify prospective partners and leading dealmakers – Discover companies with demonstrated interest in psychiatry assets, technologies, therapeutic indications, targets and relevant stages of development.

✔ Compare activity across the psychiatry landscape – Analyze dealmaking by therapeutic indication and target, development stage, technology type, deal type, industry sector and company.

✔ Find the most relevant comparable transactions – Move beyond broad averages to identify deals involving similar indications, targets, mechanisms, technologies, development stages and partnering structures.

✔ Understand how psychiatry deals are structured – Examine licensing rights, development responsibilities, exclusivity, IP, commercialization rights, milestones, royalties and other important transaction provisions.

✔ Learn from real contract documents – Where publicly available, review underlying agreements to understand how rights, obligations, financial terms and other negotiated provisions have been documented.

✔ Apply the intelligence to your own psychiatry opportunity – Qualifying customers may also be eligible for a Customized Executive Partnering Briefing focused on their own asset, indication, target, technology, prospective partners or transaction objectives.

Executive Summary

 

Chapter 1 – Introduction

 

Chapter 2 – Trends in psychiatry dealmaking

 

2.1. Introduction

2.2. Psychiatry partnering over the years     

2.3. Psychiatry partnering by deal type

2.4. Psychiatry partnering by industry sector

2.5. Psychiatry partnering by stage of development

2.6. Psychiatry partnering by technology type

2.7. Psychiatry partnering by therapeutic indication

 

Chapter 3 – Financial deal terms for psychiatry partnering

 

3.1. Introduction

3.2. Disclosed financials terms for psychiatry partnering

3.3. Psychiatry partnering headline values

3.4. Psychiatry deal upfront payments

3.5. Psychiatry deal milestone payments

3.6. Psychiatry royalty rates

 

Chapter 4 – Leading psychiatry deals and dealmakers

 

4.1. Introduction

4.2. Most active in psychiatry partnering

4.3. List of most active dealmakers in psychiatry    

4.4. Top psychiatry deals by value

 

Chapter 5 – Psychiatry contract document directory

                                            

5.1. Introduction

5.2. Psychiatry partnering deals where contract document available

 

Chapter 6 – Psychiatry dealmaking by therapeutic target

 

6.1. Introduction

6.2. Deals by psychiatry therapeutic target

 

Deal directory

 

Deal directory – Psychiatry deals by company A-Z

Deal directory – Psychiatry deals by technology type

 

Deal type definitions

 

About Biopharma Research Ltd

 

Current Partnering

Current Agreements

Recent report titles from Current Partnering

 

Table of figures

 

Figure 1: Psychiatry partnering since 2019

Figure 2: Psychiatry partnering by deal type since 2019

Figure 3: Psychiatry partnering by industry sector since 2019

Figure 4: Psychiatry partnering by stage of development since 2019

Figure 5: Psychiatry partnering by technology type since 2019

Figure 6: Psychiatry partnering by indication since 2019

Figure 7: Psychiatry deals with a headline value

Figure 8: Psychiatry deals with upfront payment values

Figure 9: Psychiatry deals with milestone payment

Figure 10: Psychiatry deals with royalty rates

Figure 11: Active psychiatry dealmaking activity since 2019

Figure 12: Top psychiatry deals by value since 2019

Pricing options

• $3,995: single-user (encrypted file - one user/device)
• $5,995: multi-user (encrypted file - up to 5 users/devices)
• $7,995: company (unencrypted file)

Single and Multi-user license files are encrypted PDF documents. Details of how to access using Javelin3 PDF Reader will be provided at report delivery.

Company license files are not encrypted and can be accessed using a PDF Reader.

A full explanation of license type definitions can be found here.

 

Our guarantee

 

Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.

 

Delivery Deadline

We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)

 

Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.

 

Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.

All card payments are processed by Evalon.

 

Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.

3Z, Abbvie, Ab Initio, ABL Bio, ABVC BioPharma, Acer Therapeutics, Ache, AC Immune, Actigraph, Aculys Pharma, Acumen Pharmaceuticals, AcuraStem, Adare Pharma Solutions, Addex Therapeutics, ADEL, ADx NeuroSciences, AffaMed Therapeutics, AgeX Therapeutics, AiBtl BioPharma, AiCure, Aiforia Technologies, AI Longevity, AimedBio, Aitia, Aker BioMarine, Akili Interactive Labs, Akome Biotech, Alamar Biosciences, Albert Einstein College of Medicine, Alchemab, Alchemab Therapeutics, Alector, Alexander Shulgin Research Institute, Alex Therapeutics, Algernon Pharmaceuticals, Alkermes, Allegori, Allied Corp, Alligator Bioscience, Alnylam Pharmaceuticals, Alpha Cognition, Altasciences, Alterity Therapeutics, Alternative Solutions, Altoida, Alto Neuroscience, Alvogen, Alzamend Neuro, Alzheimer's Association, Alzheimer's Drug Discovery Foundation, Alzheimer's Foundation of America, Alzheimer's Research UK, Alzheon, ALZpath, AlzProtect, Amerigen Pharmaceuticals, Amydis, ANANDA Scientific, Anavex Life Sciences, Ancora Bio, Angelini Pharma, Annovis Bio, Apollo Health, APRINOIA Therapeutics, Aptamer Therapeutics, AptarGroup, Aptinyx, Aquinnah Pharmaceuticals, Arbormentis, Arcade Therapeutics, Arctic Therapeutics, Ariana Pharma, AriBio, Ashvattha Therapeutics, Astellas Pharma, Astex Pharmaceuticals, ATAI Life Sciences, Atalanta Therapeutics, Athira Pharma, Attralus, Autism Impact Fund, Autism Learning Partners, Avadel Pharmaceuticals, Avance Clinical, Avata Biosciences, Avecho Biotechnology, AviadoBio, Avicanna, Awakn Life Sciences, AxoSim, Axsome Therapeutics, Aytu BioPharma, Banner Alzheimer's Institute, Barrow Neurological Institute, Baszucki Brain Research Fund, Battelle Memorial Institute, Bayer, Baylor College of Medicine, BC Neuroimmunology, Beacon Biosignals, Beckley Psytech, Beckman Coulter, BehaVR, Beth Israel Deaconess Medical Center, BetterLife Pharma, Bicycle Therapeutics, BioArctic AB, biOasis Technologies, Biodextris, Biogen, Biogenysis, Biohaven Pharmaceuticals, BioMed X Innovation Center, BioPep, Bioprojet, bioRASI, BioScript Solutions, Biotx.ai, Bird Foundation, Blum Center for Health, Boehringer Ingelheim, Bolden Therapeutics, Bora Pharmaceuticals, Boston University, Brain & Behavior Research Foundation, Brain Balance Achievement Centers, Brain Canada, BrainLAB, Brain Scientific, Braxia Scientific, Breakthrough Discoveries for Thriving with Bipolar Disorders Foundation, Breath of Life International, Bredis Healthcare, BridGene Biosciences, Brigham and Women's Hospital, Bristol-Myers Squibb, Broad Institute, Burke Neurological Institute, C2N Diagnostics, C4 Therapeutics, Cadent, Cala Health, Cambridge Brain Sciences, Cambridge Cognition, Camino Pharma, CAMP4 Therapeutics, Canadian Armed Forces, Canadian Institutes of Health Research, Canary Speech, Cantex Pharmaceuticals, Cardiff University, Carnegie Mellon University, Cassava Sciences, Catalent, CB2 Insights, CB Therapeutics, Cedar Clinical Research, Celgene, Centene, Centessa Pharmaceuticals, Centre for Addiction and Mental Health, Cerebral, Cerevance, Cerevel Therapeutics, Cerveau Technologies, Charite Universitatsmedizin Berlin, Charles River Laboratories, Charlotte's Web, Chattanooga Center for Neurologic Research, Children's Hospital of Philadelphia, China Medical System, Cingulate, Circular Genomics, Citrine Medicine, City of Hope, CKD Bio, Clalit Health Services, Clario, Clearmind Medicine, Cleveland Clinic, Clexio, Click Therapeutics, Clinilabs, Clinlogix, CND Life Sciences, Cognition Therapeutics, Cognito Therapeutics, Cognoa, CogState, Columbia University, Combat Stress, Commave Therapeutics, COMPASS Pathways, Complutense University of Madrid, ConSynance Therapeutics, Core One Labs, Corium International, Cortechs.ai, Covar Pharmaceuticals, Coya Therapeutics, CTD Holdings, Curebase, Cure Genetics, Cure Network Dolby Acceleration Partners, CURE Pharmaceutical, Cureverse, Cybin, Cyclerion Therapeutics, Cyclo Therapeutics, Cytox, Daiichi Sankyo, Dalriada Drug Discovery, Data Tecnica International, Deakin University, Deep Cube, Dementia Discovery Fund, Dementia Research Institute, Denali Therapeutics, Denovo Biopharma, Department of Defense, Department of Veterans Affairs, Develco Pharma, Diadem, DiagnaMed, DiamiR, Diamond Therapeutics, Digestome Therapeutics, Digital Medicine Society, DTx Pharma, Eagle Pharmaceuticals, EA Pharma, EIP Pharma, Eisai, Eli Lilly, Elite Pharmaceuticals, Empower Sleep, Endotherm, Enigma Biomedical, Enosis Therapeutics, Enterin, Enveric Biosciences, ERP Biomarker Qualification Consortium, Essential Pharmaceuticals, Estee Lauder, Esteve, ESYA Labs, Eureka Eurostars, Eurofarma, European Wellness Biomedical Group, EverInsight Therapeutics, Eversana, Evotec, Exeltis, Expansion Therapeutics, Expesicor, Exscientia, Fabre Kramer Pharmaceuticals, Feinstein Institute for Medical Research, Field, Filament Health, FINGERS Brain Health Institute, Firefly Neuroscience, Florida Atlantic University Research, Fluence, Forian, Four H, Frametact, Freespira, Frontage Clinical Services, FSD Pharma, Fujirebio Diagnostics, Fuzionaire Diagnostics, GABA Therapeutics, Gaia, Gain Therapeutics, Gate Neurosciences, Gedeon Richter, Geisinger Health System, Genentech, General Genomics, Genetika+, GeNeuro, Geneva University Hospitals, Genomind, Genova Diagnostics, Gentex, Georgetown University, Gilgamesh Pharmaceuticals, GL Brands, Glimpse Group, Global Alzheimer's Platform (GAP), Global Down Syndrome Foundation, Glysious, GN Group, GNS Healthcare, Golden Meditech, Goldfinch Bio, Government of South Korea, Graviton Bioscience, Gray Matter, GrayMatters Health, Green Valley Pharmaceutical, GSK, GTx, Gurnet Point Capital, Hackensack Meridian Health, Hadassah Brain Labs Center, Halberd, Halia Therapeutics, Halozyme Therapeutics, Halucenex Life Sciences, Hangzhou Highlightll Pharmaceutical, Hapbee Technologies, Happify Health, Harmony Biosciences, Harvard College, Harvard Medical School, Harvard University, Healis Therapeutics, Hebrew University of Jerusalem, HekaBio, Helsinki University Central Hospital (HUCH) Comprehensive Cancer Center, Herophilus, Hesperos, HLS Therapeutics, HMNC Brain Health, Hollister Biosciences, Holmusk, Hong Kong Baptist University, Horizon Europe, Hoth Therapeutics, HP, Hummingbird Diagnostics, Hygtia Therapeutics, Hyloris Pharmaceuticals, Hypersomnia Foundation, I-mab, IAMA Therapeutics, Icahn School of Medicine at Mount Sinai, Idorsia, Imeka, Impax Laboratories, Impression Healthcare, Inagene Diagnostics, Incannex Healthcare, Inexia, Infineon, Infinity BiologiX, InformedDNA, iNGENu, INmune Bio, Innosuisse, Innovate UK, Inscopix, InSightec, Insilico Medicine, Insitro, Institute for Molecular Medicine, Institute for Research in Biomedicine, Institute of Organic Chemistry and Biochemistry, Integrated Micro-Chromatography Systems, IntelGenx, Intellipharmaceutics, International Flavors and Fragrances, Inventia Healthcare, Inventum Genetics, inviCRO, Invo Healthcare, Ionian University, Ionis Pharmaceuticals, IQVIA, Ironshore Pharmaceuticals, IsoPlexis, Italfarmaco, Itamar Medical, iX Biopharma, IXICO, JADBio, Jaguar Health, Janssen Biotech, Janssen Pharmaceuticals, Janssen Pharmaceutica NV, Janssen Research & Development, Japan Tobacco, Jazz Pharmaceuticals, JCR Pharmaceuticals, JelikaLite, Jewel-Osco, Jiangsu NHWA Pharmaceutical, Johns Hopkins University, Jolly Good, Journey Clinical, Juvenile Bipolar Research Foundation, Karuna Therapeutics, Keio Gijuku University, Kelai Pharmaceuticals, KemPharm, Ketabon, Ketamine Infusions Centers of Texas, KeyWise, KGK Science, Khalpey AI Lab, Kindeva Drug Delivery, Kings College London, KT Corporation, KYE Pharmaceuticals, L-3 Communications, Laboratorios Bago, LANGaware, La Paz Hospital, Leidos, Lenica Research Group, LEXEO Therapeutics, Libra International, Lieber Institute, Liechti Lab, Lighthouse Pharmaceuticals, Limbix, Linical, Litesprite, LivaNova, Livzon Pharmaceutical, Longeveron, Lotus Pharmaceuticals, Lovell Government Services, LTS Lohmann Therapie-Systeme, Luca Healthcare, LUCID, Lundbeck, Luxna Biotech, Luye Pharma Group, Maastricht University, Magdalena Biosciences, Magellan Healthcare, Magic Leap, Marinus Pharmaceuticals, Marubeni, Massachusetts General Hospital, Mayo Clinic, McGill University, McLean Hospital, McMaster University, McQuade Center for Strategic Research and Development, MedBridge, Medical Food Solutions Research, Medical University South Carolina, Medicines Discovery Catapult, MediPharm Labs, Medison Pharma, Medomie Pharma, MedPharm, Meilleur Technologies, Merck and Co, Meru Health, Metabolon, Michael J Fox Foundation, Michigan State University, Microsoft, Milagro Pharmaceuticals, Milken Institute Center for Public Health, MiNA Therapeutics, MindBio Therapeutics, Mind Medicine, Mindset Pharma, MindShift Compounds, MindX Sciences, Miralogx, Mira Pharmaceuticals, Mitacs, MitoCanada Foundation, Mitochondrial Innovation Initiative, MitoSense, Mitsubishi Tanabe Pharma, MMS, Mochida Pharmaceutical, Moleculera Labs, Monash University, Montefiore Health System, Montreal Heart Institute, Montreal Neurological Institute-Hospital, Morgan Stanley, Morris Animal Foundation, Mosanna Therapeutics, MSN Laboratories, MSN Pharmaceuticals, Multidisciplinary Association for Psychedelics Studies, Muna Therapeutics, MyClearStep, MycoMedica Life Sciences, Mydecine Group, MYND Life Sciences, Myung In Pharm, Naason Science, Nacuity Pharmaceuticals, National Disease Research Interchange, National Healthcare Services (NHS), National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of General Medical Sciences, National Institute of Health Research, National Institute of Mental Health, National Institute on Aging, National Institute on Drug Abuse (NIDA), National Institutes of Health, Navidea Biopharmaceuticals, Navitor Pharmaceuticals, Negev Labs, Neomorph, NeonMind Biosciences, NervGen Pharma, NeuCyte, Neumora Therapeutics, Neuraly, Neuraxpharm, Neurimmune Therapeutics, Neurim Pharmaceuticals, Neuro Bio, NeuroBiogen, Neurocode, Neurocrine Biosciences, NeuroFront, NeuroLex Laboratories, Neurolief, Neurolixis, NeuroLucent, Neuronetrix, NeuroNexus, Neuronic, NeuroSense Therapeutics, NeuroSigma, Neurotrack, NeuroTracker, Neurotrope BioScience, Neurovation Labs, Newly Institute, Newron Pharmaceuticals, New York Presbyterian/Columbia, Nippon Shinyaku, NKGen Biotech, NLS Pharmaceutics, NOCD, Noema Pharma, Northwestern University, Novartis, Novoron Bioscience, NRx Pharmaceuticals, Nucro Technics, Numerate, Nurosene, NYU Grossman School of Medicine for Preclinical and Clinical Research, Oceanus Bio, Oligomerix, One Mind for Research, Onera Health, Ono Pharmaceutical, Optina Diagnostics, OptiNose, Orexia Therapeutics, Orexo, Orion, Orionis Biosciences, Oryzon, Ossianix, Othair Prothena, Otsuka, Ottawa Hospital Research Institute, Ovid Therapeutics, OWP Pharmaceuticals, Parexel, Parkinson's UK, Pasithea Therapeutics, Passage Bio, Patient-Centered Outcomes Research Institute, PaxMedica, PEAR Therapeutics, Pediatrix Therapeutics, Perception Neuroscience, Pfizer, PGI Drug Discovery, Phanes Therapeutics, Pharmanovia, PharmaTher, Pharmidex, Pierre Fabre, PINC AI Applied Sciences, PoloMar Health, PostEra, Praetego, Prasco Laboratories, Precision NeuroMed, Predictmedix, Premier Inc, Pritzker Group, Prometheus Laboratories, ProMIS Neurosciences, Prothena, Protxx, Providence, Psilera, Psycheceutical Bioscience, Psychedelic Society Belgium, PsychoGenics, Psylo, Pulvinar Neuro, PureTech Health, Purina, PurMinds NeuroPharma, Q2 Solutions, QIAGEN, QuantalX Neuroscience, Quanterix, Quebec Consortium for Drug Discovery, Quest Diagnostics, Quince Therapeutics, QurAlis, Radboud University Nijmegen, Rainwater Charitable Foundation, RARE-X, Readout Health, Regenerative Medicine of Latin America, Regenxbio, Relmada Therapeutics, Reputable Health, Reset Pharmaceuticals, RespireRx Pharmaceuticals, RetiSpec, RetroBrain, Reverie Labs, Revitalist Lifestyle and Wellness, Revive Therapeutics, Ro, Roche, Rockefeller University, RogCon Biosciences, Rosalind Franklin University of Medical Sciences, Royalty Pharma, Rugen Therapeutics, Rx.Health, SABI Mind, Sage Bionetworks, Sage Therapeutics, Salipro Biotech, Samsung Biologics, Sandoz, Sanford Burnham Institute, Sanford Health, Sangamo Therapeutics, Saniona, Sanofi, Sansero Life Sciences, Santa Clara University, Sawai Pharmaceuticals, Schenker Technologies, Schrodinger, Science 37, Scilex Holding, SciNeuro Pharmaceuticals, SciSparc, Scripps Research Institute, Seed Therapeutics, Seelos Therapeutics, Selonterra, Sentia Medical Sciences, Seqster, Sequentify, Shanghai Ark Biopharmaceutical, Shanghai Mental Health Center, Shape Therapeutics, Shionogi, Shionogi Pharma, Siemens Healthineers, Signant Health, Silo Pharma, SilverCloud Health, Sirion Biotech, Skyhawk Therapeutics, Sleep Consortium, Sleepiz, SleepScore Labs, Societal CDMO, SoftBank, Sosei, Sosei Heptares, Southwest College of Naturopathic Medicine & Health Sciences, Spacelabs Healthcare, Spark Biomedical, Spear Bio, Sphere Health, Spinogenix, SpringWorks Therapeutics, Spruce Biosciences, STADA Arzneimittel, Stalicla, Stanford University, Stanford University School of Medicine, Stem of Hope, Stratus Research Labs, St Vincent’s Institute of Medical Research, SUDA Pharmaceuticals, Sumitomo Dainippon Pharma, Sumitomo Pharmaceuticals, Sunovion Pharmaceuticals, Sunstone Therapies, Supernus Pharmaceuticals, Swinburne University, Sylics Contract Research, Synaffix, Syneos Health, Synova Healthcare, Sysmex, T-NeuroDx, T3D Therapeutics, Tabula Rasa HealthCare, Tactical Relief, Taisho Pharmaceutical, Takeda Pharmaceutical, Takeda Pharmaceuticals U.S.A, TALi, Taliaz, Technology University Dresden, Teijin, Tempus, Terran Biosciences, Tetra Pharm Technologies, Teva Pharmaceutical Industries, The Jackson Laboratory, The New York Stem Cell Foundation, Therapeutic Solutions International, Tivic Health Systems, TMS NeuroHealth Centers, TONIX Pharmaceuticals, Toronto Centre for Psychedelic Science, Total Brain, Towa Pharmaceutical, Transcend Therapeutics, Transition Bio, TrialSpark, Tridiuum, Tris Pharma, TruGenomix, Tryp Therapeutics, Tymora Analytical Operations, UCB, Undisclosed Company, University Health Network, University of Barcelona, University of British Columbia, University of Calgary, University of California, Davis, University of California, San Diego, University of California Berkeley, University of California Irvine, University of California Los Angeles, University of California San Francisco, University of Colorado, University of East London, University of Exeter, University of Florida, University of Guelph, University of Iowa, University of Lethbridge, University of Marburg, University of Maryland Baltimore, University of Miami, University of Michigan, University of Mississippi, University of Missouri, University of Nebraska, University of North Carolina, University of Oslo, University of Oxford, University of Pennsylvania, University of Pittsburgh, University of Saskatchewan, University of Southern California, University of Texas, University of Texas Health Science Center at Houston, University of Toronto, University of Washington, University of Wisconsin, Uppsala University, US Air Force, UWM Research Foundation, Vaccinex, Vanda Pharmaceuticals, Vanderbilt University, Vandria, Vaxxinity, Vect-Horus, Vektor Pharma, Veltmeyer MD, VeraSci, Veravas, Verge Genomics, Verily, Verix, Vibrent Health, ViewMind, Viome, Virginia Commonwealth University, Visiopharm, VistaGen Therapeutics, VitalHub, Vitro Biopharma, Vivos Therapeutics, VoxNeuro, Voyager Therapeutics, Walgreens, Washington University in St Louis, WAVE Life Sciences, Weill Cornell Medical College, Willow Biosciences, WinterLight Labs, Wise Therapeutics, Worldwide Clinical Trials, Wren Therapeutics, Xenon Pharmaceuticals, XRHealth, XWPharma, Yale School of Medicine, Yale University, Yamo Pharmaceuticals, Yeda Research and Development Company, Yissum Research Development, Young Blood Institute, Yumanity Therapeutics, ZAI Laboratory, Zambon, Zelira Therapeutics, Zevra Therapeutics, Zhittya Genesis Medicine, Zhongze Therapeutics, ZYUS Life Sciences

About Current Partnering

A definitive, evidence-based approach to dealmaking intelligence

Current Partnering is the industry-leading provider of pharmaceutical and biotech dealmaking intelligence, delivering a clear, structured, and evidence-based view of how partnerships are designed, negotiated, and executed in practice.

Our reports combine comprehensive deal coverage, structured data analysis, and contract-level insight, enabling a deeper understanding of how financial terms, rights, and responsibilities are defined across real-world transactions.

All reports are updated every six months, ensuring users have access to the latest deal activity, trends, and market developments.

---

Our methodology

Built on a continuously updated proprietary database

All analysis is underpinned by Current Agreements, our proprietary deals and alliances database which is updated daily by our analysts as new transactions are announced globally.

Deal records are continuously reviewed and enriched as additional information becomes available, ensuring accuracy, completeness, and relevance.

---

Comprehensive and verifiable data sourcing

Deal data is sourced from publicly available industry disclosures, including:

• Company press releases and announcements
• SEC filings and equivalent regulatory disclosures
• Company and investor presentations
• Conference materials and company websites

All sources are captured and referenced, enabling full transparency and user verification.

---

Broad coverage across deal types and structures

Current Partnering provides comprehensive coverage across a wide range of deal types, including but not limited to:

• Licensing and co-development
• Research and collaborative R&D
• Manufacturing, supply, and distribution
• Commercialisation and co-promotion
• Equity investments, joint ventures, and asset transactions
• Options, royalties, and financing agreements

This breadth ensures a complete view of how partnerships are structured across the life sciences sector.

---

Structured, standardised analysis

Every deal is analysed using a consistent framework, capturing (where disclosed):

• Financial terms — including upfront payments, milestones, and royalties
• Rights allocation — development, manufacturing, and commercialization responsibilities
• Deal structure — exclusivity, territorial scope, and agreement type
• Contractual provisions — clauses defining risk, control, and value-sharing

Each deal record is fully categorised, including data fields such as:

• Therapy area and technology type
• Stage of development
• Asset type and deal components
• Geographic scope and exclusivity
• Source documentation, including press releases and SEC filings

---

Financial normalisation for comparability

All financial values are standardised to USD using the exchange rate at the time of deal announcement, enabling consistent comparison of deal terms across geographies.

---

Contract-level insight

Where available, reports include direct access to underlying agreement documents, providing visibility into how deals are constructed in practice.

This enables users to understand:

• How financial mechanisms are defined and triggered
• How responsibilities are operationalised between parties
• How flexibility, risk, and control are allocated within agreements

---

Designed for real-world application

Current Partnering reports are built to support business-critical decision-making across the life sciences ecosystem, including:

• Pharmaceutical and biotech companies — benchmarking deals, structuring transactions, and supporting licensing strategy
• Investment firms and venture capital — assessing deal benchmarks, valuation expectations, and partner behaviour
• Advisory, legal, and consulting firms — supporting client engagements with real-world precedent and contract-level insight

Common use cases include:

• Benchmarking comparable transactions
• Supporting valuation and deal structuring
• Preparing for negotiations
• Evaluating potential partners
• Informing internal strategy with real-world evidence

---

A trusted industry reference

With a long track record in the sector, Current Partnering is relied upon by leading pharmaceutical companies, emerging biotechs, investors, and advisory firms as a trusted source of dealmaking intelligence.

By combining proprietary data, rigorous methodology, and contract-level insight, our reports provide a reliable and authoritative foundation for understanding how deals are structured, negotiated, and valued.